Meet the Experts

Chris joined sixsense as an intern after completing his Master’s degree in Biotechnology at McGill University. Before this, he attended the University of Waterloo, where he got his HBSc in Microbiology. Throughout his studies, Chris had the opportunity to work as a co-op student at various Life Sciences organizations like Sanofi Pasteur and academic labs.

When he wasn’t performing experiments for his graduate degree, Chris focused on growing his business acumen by enrolling in MBA and Law School courses. He also participated in case competitions and workshops through various academic consulting organizations. By the end of his Master’s experience, he had been included in multiple Scientific Publications looking at novel vaccine candidates, written his Thesis in Microbiology/Immunology, and completed a specialization in Business & Policy.

Chris has grown to become a Senior Leadership Team member at Sixsense Strategy Group where he leads various strategic and medical clients and projects, while helping the organization grow.

When he isn’t helping develop strategy for his clients, Chris can be found enjoying nature, hiking somewhere in the forest. That, or watching Football (European, not American).

Thought Leadership

Medical Affairs
- Article: Part 4: Navigating success during a rare disease product launch
  The video outlines best planning, timing, and budgeting practices in rare disease product launches. Watch here.
- Article: Navigating success during a rare disease product launch
  In this video, experts Kapil Raina, Chris Zealey, and Brian Williams, explore insights on successfully launching products in rare disease markets.
- Article: Part 3: Navigating success during a rare disease product launch
  The video outlines key success factors in rare disease markets through the five P's: People, Product, Payers, Promotion, and Placement. Watch here.
- Article: Part 2: Navigating success during a rare disease product launch
  Gain insights from Chief Commercial Officers on launching in the rare disease market. Watch here.
- Case Study: Redefining the Treatment Paradigm in Mental Health
  Our client was approaching the launch of a new product for treatment of a mental health disorder. Despite promising trial data, successful adoption of their therapy would be challenging for a number of reasons. Read the case study.
- Case Study: Pioneering Treatment Paradigm in Neurology
  Discover how we assisted our client in positioning their therapy for optimal impact in the evolving landscape of steroid reduction and global treatment strategies.
- Case Study: Strategic Repositioning of a GI Market Leader Amidst Evolving Market Dynamics
  Explore how we analyzed and refined our client's drug positioning across multiple indications to ensure market alignment and strategic coherence. Read the case study.
- Case Study: Communication Strategy for Novel MOA in Neurological Disorder
  Our client aimed to apply a proven molecule to a new neurological disorder. We helped create a compelling narrative and cost-effective strategy to boost ROI. Read the case study.
- Case Study: Strategic Launch in a Rare Hematologic Disease
  Learn how we navigated the challenges of launching a novel treatment in a rare hematologic disease to position our client's drug as a potential new standard of care. Read the full case study.
- Article: Part 1: Navigating success during a rare disease product launch
  Explore the rare disease landscape, focusing on patients' diagnostic and treatment challenges, competitive dynamics, and tailored launch strategies.
- Case Study: Development of a Scientific Platform for Biotech Client
  Our biotech client was facing the challenge of introducing a new competitor into the market while simultaneously gaining a deeper understanding of their disease state. To navigate this complex scenario, they needed a strategic document that would serve as the foundation for both internal and external communications.
- Case Study: KOL Identification and Engagement Planning in Rare Disease Clinical Development
  Our client, a leading biopharmaceutical company, sought to embark on a clinical development program within a new therapeutic area in the rare disease space. Read the case study.
- Article: Unveiling Insights: How KOLs Shaped a Groundbreaking Therapy’s Journey
  A recent pivotal Phase 3 clinical trial marked a significant milestone for our client, a biopharmaceutical company, in their quest to introduce a novel treatment for major depressive disorder (MDD). Read more.